BIENAIME JEAN JACQUES (CIK 1221590) reported 22 SEC Form 4 insider transactions across 4 companies over the past 18 months (most recent 2026-06-17). Recent activity: Buy KROS (1,000 shares), Buy INCY (1,642 shares), Sell IMNM (500 shares), Sell IMNM (10,000 shares), Buy IMNM (6,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 1,000 | $10,190 |
| 2026-06-10 | INCYTE CORP (INCY) | Director | Buy | 1,642 | $0 |
| 2026-06-09 | Immunome Inc. (IMNM) | Director | Sell | 500 | $9,720 |
| 2026-06-09 | Immunome Inc. (IMNM) | Director | Sell | 10,000 | $194,100 |
| 2026-06-09 | Immunome Inc. (IMNM) | Director | Buy | 6,000 | $116,880 |
| 2026-06-09 | Immunome Inc. (IMNM) | Director | Buy | 3,500 | $68,110 |
| 2026-06-09 | Immunome Inc. (IMNM) | Director | Buy | 1,000 | $19,270 |
| 2026-06-05 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 7,142 | $0 |
| 2026-06-01 | Ascendis Pharma A/S (ASND) | Director | Buy | 200 | $44,752 |
| 2026-06-01 | Ascendis Pharma A/S (ASND) | Director | Buy | 200 | $44,460 |
| 2026-06-01 | Ascendis Pharma A/S (ASND) | Director | Buy | 100 | $22,350 |
| 2026-05-19 | Immunome Inc. (IMNM) | Director | Buy | 5,000 | $103,500 |
| 2026-05-19 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 1,000 | $10,580 |
| 2026-04-17 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 1,000 | $11,700 |
| 2026-03-12 | Immunome Inc. (IMNM) | Director | Buy | 1,000 | $22,120 |
| 2026-03-12 | Immunome Inc. (IMNM) | Director | Buy | 1,000 | $21,550 |
| 2026-03-11 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 2,000 | $22,420 |
| 2025-06-12 | INCYTE CORP (INCY) | Director | Buy | 2,518 | $0 |
| 2025-06-06 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 5,250 | $0 |
| 2025-06-03 | Immunome Inc. (IMNM) | Director | Buy | 5,000 | $46,900 |
| 2025-03-26 | Immunome Inc. (IMNM) | Director | Buy | 7,800 | $60,684 |
| 2025-03-25 | Immunome Inc. (IMNM) | Director | Buy | 7,000 | $57,470 |
Source: SEC Form 4 filings · as of 2026-06-17